GSK plc
Related Filers (73)
- GLAXOSMITHKLINE CAPITAL PLC (46)
- Innoviva, Inc. (39)
- GLAXOSMITHKLINE CAPITAL INC (36)
- HUMAN GENOME SCIENCES INC (19)
- Theravance Biopharma, Inc. (19)
- QUEST DIAGNOSTICS INC (16)
- GENOCEA BIOSCIENCES, INC. (14)
- BlackRock Inc. (13)
- Spero Therapeutics, Inc. (13)
- NEW YORK STOCK EXCHANGE LLC (11)
- GENELABS TECHNOLOGIES INC /CA (10)
- TESARO, Inc. (10)
- AMICUS THERAPEUTICS INC (9)
- HTG MOLECULAR DIAGNOSTICS, INC (9)
- BICYCLE THERAPEUTICS plc (9)
- APPLIED GENETIC TECHNOLOGIES CORP (8)
- CRISPR Therapeutics AG (8)
- ChemoCentryx, Inc. (8)
- Principia Biopharma Inc. (8)
- NUPATHE INC. (7)
- Turning Point Therapeutics, Inc. (7)
- Morphic Holding, Inc. (7)
- AFFYMETRIX INC (6)
- MAXYGEN INC (6)
- Anacor Pharmaceuticals, Inc. (6)
- Translate Bio, Inc. (6)
- EPIX Pharmaceuticals, Inc. (5)
- PRAECIS PHARMACEUTICALS INC (5)
- CONCERT PHARMACEUTICALS, INC. (5)
- Progyny, Inc. (5)
- Nkarta, Inc. (5)
- Haleon plc (5)
- CORIXA CORP (4)
- Redpoint Bio CORP (4)
- AILERON THERAPEUTICS INC (4)
- Pandion Therapeutics, Inc. (4)
- CVRx, Inc. (4)
- Fulcrum Therapeutics, Inc. (4)
- 23andMe Holding Co. (4)
- Wave Life Sciences Ltd. (4)
- PACIFICHEALTH LABORATORIES INC (3)
- TRANSGENOMIC INC (3)
- TARGACEPT INC (3)
- Sirtris Pharmaceuticals, Inc. (3)
- Regulus Therapeutics Inc. (3)
- OncoMed Pharmaceuticals Inc (3)
- Lyell Immunopharma, Inc. (3)
- JPMorgan Chase Bank, N.A. - ADR Depositary (3)
- DODGE & COX (3)
- CIPHERGEN BIOSYSTEMS INC (2)
- S R ONE (2)
- MEMORY PHARMACEUTICALS CORP (2)
- SMITHKLINE BEECHAM CORP (2)
- ADHEREX TECHNOLOGIES INC (2)
- CYTOKINETICS INC (2)
- AFFYMAX INC (2)
- Diadexus, Inc. (2)
- RESPONSE GENETICS INC (2)
- SCYNEXIS INC (2)
- Liquidia Technologies Inc (2)
- Orchard Therapeutics plc (2)
- CureVac N.V. (2)
- Decibel Therapeutics, Inc. (2)
- F-star Therapeutics, Inc. (2)
- Vir Biotechnology, Inc. (2)
- CARESIDE INC (1)
- CONNETICS CORP (1)
- CNS INC /DE/ (1)
- XENOPORT INC (1)
- CADUS CORP (1)
- BANK OF NEW YORK / ADR DIVISION (1)
- CONSTELLATION PHARMACEUTICALS INC (1)
- Sierra Oncology, Inc. (1)
- Show More ...
Other (5660)
6-K
Thursday, 2/15/2024
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Thursday, 2/15/2024
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 2/13/2024
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 2/13/2024
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 2/13/2024
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 2/12/2024
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 2/12/2024
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 2/12/2024
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 2/12/2024
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 2/6/2024
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 2/6/2024
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 2/6/2024
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Thursday, 2/1/2024
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Thursday, 2/1/2024
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Thursday, 2/1/2024
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 1/31/2024
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 1/29/2024
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 1/29/2024
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Friday, 1/19/2024
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 1/17/2024
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 1/17/2024
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 1/17/2024
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 1/16/2024
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 1/10/2024
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 1/9/2024
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 1/2/2024
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Thursday, 12/21/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 12/18/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 12/13/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 12/12/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 12/11/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 12/4/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Friday, 12/1/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Thursday, 11/30/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 11/29/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 11/27/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 11/21/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 11/15/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 11/13/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 11/13/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 11/1/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 11/1/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 10/30/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Thursday, 10/26/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 10/25/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 10/25/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Friday, 10/20/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 10/18/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 10/17/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 10/16/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Friday, 10/13/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Thursday, 10/12/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 10/11/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 10/10/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Friday, 10/6/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Friday, 10/6/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 10/2/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
25-NSE
Monday, 10/2/2023
Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
6-K
Wednesday, 9/27/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 9/25/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Thursday, 9/21/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 9/19/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 9/18/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 9/13/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 9/11/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 9/11/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 9/6/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Friday, 9/1/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Friday, 9/1/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Thursday, 8/31/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Thursday, 8/31/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Friday, 8/25/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 8/23/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 8/23/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 8/22/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Thursday, 8/10/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 8/9/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 8/1/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 7/31/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 7/31/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Friday, 7/28/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 7/26/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 7/24/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Thursday, 7/20/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 7/17/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Thursday, 7/13/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 7/3/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 6/28/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 6/27/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 6/26/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 6/26/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Friday, 6/23/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Friday, 6/23/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Friday, 6/23/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Friday, 6/23/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Thursday, 6/22/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
11-K
Wednesday, 6/21/2023
Annual report of employee stock purchase, savings and similar plans
6-K
Wednesday, 6/21/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
11-K
Wednesday, 6/21/2023
Annual report of employee stock purchase, savings and similar plans
6-K
Friday, 6/16/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Ownership (330)
SC 13G/A
Tuesday, 2/13/2024
DODGE & COX: Major Shareholders
SC 13D/A
Friday, 2/9/2024
23andMe Holding Co.: Major Shareholders
SC 13G/A
Tuesday, 2/6/2024
Wave Life Sciences Ltd.: Major Shareholders
SC 13G/A
Tuesday, 2/6/2024
CureVac N.V.: Major Shareholders
4
Tuesday, 1/30/2024
Wave Life Sciences Ltd.: Statement of changes in beneficial ownership of securities
SC 13D/A
Friday, 1/19/2024
Haleon plc: Major Shareholders
SC 13D/A
Tuesday, 10/10/2023
Haleon plc: Major Shareholders
SC 13D/A
Monday, 9/11/2023
Haleon plc: Major Shareholders
SC 13D/A
Thursday, 7/20/2023
BICYCLE THERAPEUTICS plc: Major Shareholders
SC 13D/A
Tuesday, 5/16/2023
Haleon plc: Major Shareholders
SC 13G/A
Tuesday, 2/14/2023
DODGE & COX: Major Shareholders
SC 13G
Monday, 2/6/2023
CVRx, Inc.: Major Shareholders
3
Monday, 1/30/2023
Wave Life Sciences Ltd.: Initial statement of beneficial ownership of securities
SC 13G
Monday, 1/30/2023
Wave Life Sciences Ltd.: Major Shareholders
SC 13D/A
Friday, 1/20/2023
23andMe Holding Co.: Major Shareholders
SC 13D/A
Friday, 1/20/2023
Spero Therapeutics, Inc.: Major Shareholders
3
Monday, 11/14/2022
Spero Therapeutics, Inc.: Initial statement of beneficial ownership of securities
SC 13D/A
Monday, 11/14/2022
Spero Therapeutics, Inc.: Major Shareholders
SC 13D
Friday, 11/4/2022
23andMe Holding Co.: Major Shareholders
3
Friday, 11/4/2022
23andMe Holding Co.: Initial statement of beneficial ownership of securities
4
Tuesday, 9/20/2022
Theravance Biopharma, Inc.: Statement of changes in beneficial ownership of securities
SC 13D/A
Tuesday, 9/20/2022
Theravance Biopharma, Inc.: Major Shareholders
SC 13D/A
Wednesday, 8/3/2022
Theravance Biopharma, Inc.: Major Shareholders
SC 13D
Wednesday, 7/27/2022
Haleon plc: Major Shareholders
SC 13D/A
Friday, 5/13/2022
Nkarta, Inc.: Major Shareholders
SC 13G
Monday, 2/14/2022
DODGE & COX: Major Shareholders
SC 13G/A
Thursday, 2/10/2022
F-star Therapeutics, Inc.: Major Shareholders
SC 13G/A
Thursday, 2/10/2022
Vir Biotechnology, Inc.: Major Shareholders
SC 13D/A
Thursday, 2/10/2022
Theravance Biopharma, Inc.: Major Shareholders
SC 13G
Thursday, 2/10/2022
Lyell Immunopharma, Inc.: Major Shareholders
SC 13G/A
Thursday, 2/10/2022
GENOCEA BIOSCIENCES, INC.: Major Shareholders
SC 13G/A
Monday, 2/7/2022
BlackRock Inc.: Major Shareholders
SC 13G/A
Monday, 9/27/2021
Fulcrum Therapeutics, Inc.: Major Shareholders
SC 13D/A
Thursday, 9/16/2021
BICYCLE THERAPEUTICS plc: Major Shareholders
SC 13D/A
Thursday, 9/16/2021
Spero Therapeutics, Inc.: Major Shareholders
SC 13G
Monday, 7/12/2021
CVRx, Inc.: Major Shareholders
4
Tuesday, 7/6/2021
CVRx, Inc.: Statement of changes in beneficial ownership of securities
3
Tuesday, 7/6/2021
CVRx, Inc.: Initial statement of beneficial ownership of securities
4
Wednesday, 6/23/2021
Lyell Immunopharma, Inc.: Statement of changes in beneficial ownership of securities
3
Thursday, 6/17/2021
Lyell Immunopharma, Inc.: Initial statement of beneficial ownership of securities
SC 13D/A
Tuesday, 5/25/2021
Innoviva, Inc.: Major Shareholders
4
Monday, 5/24/2021
Innoviva, Inc.: Statement of changes in beneficial ownership of securities
SC 13D/A
Friday, 4/16/2021
BICYCLE THERAPEUTICS plc: Major Shareholders
SC 13D/A
Thursday, 4/8/2021
Pandion Therapeutics, Inc.: Major Shareholders
4
Friday, 2/19/2021
Decibel Therapeutics, Inc.: Statement of changes in beneficial ownership of securities
SC 13G/A
Friday, 2/12/2021
Progyny, Inc.: Major Shareholders
SC 13G/A
Friday, 2/12/2021
GENOCEA BIOSCIENCES, INC.: Major Shareholders
SC 13D/A
Friday, 2/12/2021
Innoviva, Inc.: Major Shareholders
3
Thursday, 2/11/2021
Decibel Therapeutics, Inc.: Initial statement of beneficial ownership of securities
SC 13G/A
Friday, 1/29/2021
BlackRock Inc.: Major Shareholders
SC 13D/A
Monday, 12/7/2020
BICYCLE THERAPEUTICS plc: Major Shareholders
SC 13D/A
Monday, 12/7/2020
Spero Therapeutics, Inc.: Major Shareholders
SC 13G
Monday, 11/30/2020
F-star Therapeutics, Inc.: Major Shareholders
SC 13D/A
Friday, 11/6/2020
Turning Point Therapeutics, Inc.: Major Shareholders
SC 13D/A
Thursday, 10/1/2020
Principia Biopharma Inc.: Major Shareholders
4
Friday, 9/18/2020
BICYCLE THERAPEUTICS plc: Statement of changes in beneficial ownership of securities
SC 13G
Monday, 8/24/2020
CureVac N.V.: Major Shareholders
SC 13D
Monday, 8/3/2020
Pandion Therapeutics, Inc.: Major Shareholders
4
Thursday, 7/30/2020
GENOCEA BIOSCIENCES, INC.: Statement of changes in beneficial ownership of securities
SC 13D
Wednesday, 7/22/2020
Nkarta, Inc.: Major Shareholders
4
Wednesday, 7/22/2020
Pandion Therapeutics, Inc.: Statement of changes in beneficial ownership of securities
3
Thursday, 7/16/2020
Pandion Therapeutics, Inc.: Initial statement of beneficial ownership of securities
4
Thursday, 7/16/2020
Nkarta, Inc.: Statement of changes in beneficial ownership of securities
3/A
Tuesday, 7/14/2020
Nkarta, Inc.: Initial statement of beneficial ownership of securities
SC 13D/A
Friday, 7/10/2020
CRISPR Therapeutics AG: Major Shareholders
3
Thursday, 7/9/2020
Nkarta, Inc.: Initial statement of beneficial ownership of securities
SC 13D/A
Monday, 6/29/2020
Morphic Holding, Inc.: Major Shareholders
4
Monday, 6/22/2020
Theravance Biopharma, Inc.: Statement of changes in beneficial ownership of securities
SC 13D/A
Monday, 6/22/2020
Theravance Biopharma, Inc.: Major Shareholders
SC 13D/A
Wednesday, 6/17/2020
Theravance Biopharma, Inc.: Major Shareholders
SC 13D/A
Thursday, 6/4/2020
Spero Therapeutics, Inc.: Major Shareholders
SC 13D/A
Tuesday, 5/26/2020
Turning Point Therapeutics, Inc.: Major Shareholders
4
Tuesday, 5/26/2020
Turning Point Therapeutics, Inc.: Statement of changes in beneficial ownership of securities
4
Thursday, 5/21/2020
Progyny, Inc.: Statement of changes in beneficial ownership of securities
SC 13G
Monday, 5/4/2020
Vir Biotechnology, Inc.: Major Shareholders
SC 13G/A
Friday, 2/28/2020
GENOCEA BIOSCIENCES, INC.: Major Shareholders
SC 13D/A
Thursday, 2/27/2020
Theravance Biopharma, Inc.: Major Shareholders
SC 13D/A
Tuesday, 2/18/2020
Theravance Biopharma, Inc.: Major Shareholders
SC 13D/A
Tuesday, 2/18/2020
Morphic Holding, Inc.: Major Shareholders
SC 13D/A
Friday, 2/14/2020
BICYCLE THERAPEUTICS plc: Major Shareholders
SC 13D/A
Friday, 2/14/2020
APPLIED GENETIC TECHNOLOGIES CORP: Major Shareholders
SC 13D/A
Friday, 2/14/2020
Principia Biopharma Inc.: Major Shareholders
SC 13D/A
Friday, 2/14/2020
CRISPR Therapeutics AG: Major Shareholders
SC 13D/A
Friday, 2/14/2020
Spero Therapeutics, Inc.: Major Shareholders
SC 13G
Friday, 2/14/2020
Fulcrum Therapeutics, Inc.: Major Shareholders
SC 13D/A
Friday, 2/14/2020
Translate Bio, Inc.: Major Shareholders
SC 13G
Friday, 2/14/2020
Progyny, Inc.: Major Shareholders
SC 13D/A
Friday, 2/14/2020
AILERON THERAPEUTICS INC: Major Shareholders
SC 13G/A
Friday, 2/14/2020
CONCERT PHARMACEUTICALS, INC.: Major Shareholders
SC 13G/A
Friday, 2/14/2020
GENOCEA BIOSCIENCES, INC.: Major Shareholders
SC 13G/A
Wednesday, 2/5/2020
BlackRock Inc.: Major Shareholders
3
Thursday, 1/2/2020
Orchard Therapeutics plc: Initial statement of beneficial ownership of securities
4
Thursday, 10/31/2019
Progyny, Inc.: Statement of changes in beneficial ownership of securities
3
Thursday, 10/24/2019
Progyny, Inc.: Initial statement of beneficial ownership of securities
4
Tuesday, 10/22/2019
Principia Biopharma Inc.: Statement of changes in beneficial ownership of securities
4
Thursday, 9/12/2019
Turning Point Therapeutics, Inc.: Statement of changes in beneficial ownership of securities
SC 13D/A
Thursday, 7/25/2019
Morphic Holding, Inc.: Major Shareholders
4
Wednesday, 7/24/2019
Fulcrum Therapeutics, Inc.: Statement of changes in beneficial ownership of securities
3
Wednesday, 7/17/2019
Fulcrum Therapeutics, Inc.: Initial statement of beneficial ownership of securities
SC 13D
Friday, 7/12/2019
Morphic Holding, Inc.: Major Shareholders
Prospectus (78)
424B3
Tuesday, 5/17/2022
Prospectus filed pursuant to Rule 424(b)(3)
424B3
Tuesday, 5/17/2022
Prospectus filed pursuant to Rule 424(b)(3)
424B2
Wednesday, 9/30/2020
Prospectus filed pursuant to Rule 424(b)(2)
424B2
Monday, 9/28/2020
Prospectus filed pursuant to Rule 424(b)(2)
FWP
Monday, 9/28/2020
Filing under Securities Act Rules 163/433 of free writing prospectuses
FWP
Monday, 9/28/2020
Filing under Securities Act Rules 163/433 of free writing prospectuses
S-8
Friday, 12/20/2019
Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
424B2
Wednesday, 3/20/2019
Prospectus filed pursuant to Rule 424(b)(2)
FWP
Tuesday, 3/19/2019
Filing under Securities Act Rules 163/433 of free writing prospectuses
FWP
Tuesday, 3/19/2019
Filing under Securities Act Rules 163/433 of free writing prospectuses
424B2
Monday, 3/18/2019
Prospectus filed pursuant to Rule 424(b)(2)
SC TO-T/A
Tuesday, 1/22/2019
Third party tender offer statement
SC TO-T/A
Thursday, 1/17/2019
Third party tender offer statement
SC TO-T/A
Tuesday, 1/15/2019
Third party tender offer statement
SC TO-T/A
Monday, 1/7/2019
Third party tender offer statement
SC TO-T/A
Wednesday, 1/2/2019
Third party tender offer statement
SC TO-T/A
Tuesday, 12/18/2018
Third party tender offer statement
SC TO-T/A
Monday, 12/17/2018
Third party tender offer statement
SC TO-T
Friday, 12/14/2018
Third party tender offer statement
SC TO-C
Tuesday, 12/4/2018
Written communication relating to an issuer or third party tender offer
SC TO-C
Tuesday, 12/4/2018
Written communication relating to an issuer or third party tender offer
424B2
Monday, 5/14/2018
Prospectus filed pursuant to Rule 424(b)(2)
FWP
Friday, 5/11/2018
Filing under Securities Act Rules 163/433 of free writing prospectuses
FWP
Friday, 5/11/2018
Filing under Securities Act Rules 163/433 of free writing prospectuses
FWP
Friday, 5/11/2018
Filing under Securities Act Rules 163/433 of free writing prospectuses
FWP
Friday, 5/11/2018
Filing under Securities Act Rules 163/433 of free writing prospectuses
424B2
Thursday, 5/10/2018
Prospectus filed pursuant to Rule 424(b)(2)
424B2
Friday, 3/15/2013
Prospectus filed pursuant to Rule 424(b)(2)
FWP
Thursday, 3/14/2013
Filing under Securities Act Rules 163/433 of free writing prospectuses
424B2
Wednesday, 3/13/2013
Prospectus filed pursuant to Rule 424(b)(2)
SC TO-T/A
Friday, 8/3/2012
Third party tender offer statement
SC TO-T/A
Monday, 7/30/2012
Third party tender offer statement
SC TO-T/A
Thursday, 7/26/2012
Third party tender offer statement
SC TO-T/A
Wednesday, 7/25/2012
Third party tender offer statement
SC TO-T/A
Monday, 7/23/2012
Third party tender offer statement
SC TO-T/A
Thursday, 7/19/2012
Third party tender offer statement
SC TO-T/A
Monday, 7/16/2012
Third party tender offer statement
SC TO-T/A
Friday, 6/29/2012
Third party tender offer statement
SC TO-T/A
Friday, 6/15/2012
Third party tender offer statement
SC TO-T/A
Friday, 6/8/2012
Third party tender offer statement
SC TO-T/A
Friday, 6/1/2012
Third party tender offer statement
SC TO-T/A
Wednesday, 5/23/2012
Third party tender offer statement
SC TO-T/A
Thursday, 5/17/2012
Third party tender offer statement
SC TO-T
Thursday, 5/10/2012
Third party tender offer statement
SC TO-C
Wednesday, 5/9/2012
Written communication relating to an issuer or third party tender offer
424B2
Friday, 5/4/2012
Prospectus filed pursuant to Rule 424(b)(2)
FWP
Thursday, 5/3/2012
Filing under Securities Act Rules 163/433 of free writing prospectuses
424B2
Wednesday, 5/2/2012
Prospectus filed pursuant to Rule 424(b)(2)
S-8
Wednesday, 10/28/2009
Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
SC TO-T/A
Wednesday, 1/7/2009
Third party tender offer statement
SC TO-T/A
Tuesday, 12/30/2008
Third party tender offer statement
SC TO-T/A
Monday, 12/15/2008
Third party tender offer statement
SC TO-T/A
Monday, 12/8/2008
Third party tender offer statement
SC TO-T/A
Wednesday, 12/3/2008
Third party tender offer statement
SC TO-T/A
Friday, 11/21/2008
Third party tender offer statement
SC TO-T
Wednesday, 11/12/2008
Third party tender offer statement
SC TO-C
Monday, 11/3/2008
Written communication relating to an issuer or third party tender offer
SC TO-C
Thursday, 10/30/2008
Written communication relating to an issuer or third party tender offer
SC TO-T/A
Monday, 6/2/2008
Third party tender offer statement
SC TO-T/A
Tuesday, 5/20/2008
Third party tender offer statement
424B2
Thursday, 5/8/2008
Prospectus filed pursuant to Rule 424(b)(2)
FWP
Wednesday, 5/7/2008
Filing under Securities Act Rules 163/433 of free writing prospectuses
424B2
Tuesday, 5/6/2008
Prospectus filed pursuant to Rule 424(b)(2)
FWP
Tuesday, 5/6/2008
Filing under Securities Act Rules 163/433 of free writing prospectuses
SC TO-T
Friday, 5/2/2008
Third party tender offer statement
SC TO-T/A
Thursday, 9/13/2007
Third party tender offer statement
SC TO-T
Wednesday, 8/1/2007
Third party tender offer statement
SC TO-T/A
Friday, 2/16/2007
Third party tender offer statement
SC TO-T/A
Thursday, 2/15/2007
Third party tender offer statement
SC TO-T/A
Wednesday, 2/7/2007
Third party tender offer statement
SC TO-T
Tuesday, 1/9/2007
Third party tender offer statement
SC TO-C
Thursday, 12/21/2006
Written communication relating to an issuer or third party tender offer
424B2
Thursday, 4/1/2004
Prospectus filed pursuant to Rule 424(b)(2)
424B2
Thursday, 4/1/2004
Prospectus filed pursuant to Rule 424(b)(2)
424B2
Wednesday, 3/31/2004
Prospectus filed pursuant to Rule 424(b)(2)
424B2
Wednesday, 3/31/2004
Prospectus filed pursuant to Rule 424(b)(2)
S-8
Monday, 10/7/2002
Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
S-8
Tuesday, 5/21/2002
Initial registration statement for securities to be offered to employees pursuant to employee benefit plans